Aptose Biosciences Inc. (T:APS)
Business Focus: Biotechnology & Medical Research (NEC)
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEDAR | |
| Company Contact | |
| Address: | 251 Consumers Rd Suite 1105 NORTH YORK ON M2J 4R3 |
| Tel: | N/A |
| Website: | https://aptose.com |
| IR: | See website |
| Key People | ||
| William Glenn Rice Chairman of the Board, President, Chief Executive Officer, Chief Accounting Officer | Fletcher Payne Chief Financial Officer, Senior Vice President | Rafael Bejar Senior Vice President, Chief Medical Officer | Philippe Ledru Chief Commercial Officer |
| Business Overview |
| Aptose Biosciences Inc. is a Canada-based clinical stage precision oncology biotechnology company. It is engaged in advancing kinase inhibitors to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia (AML), certain B-cell malignancies, high-risk myelodysplastic syndrome (MDS) and other hematologic malignancies. Its HM43239 is being evaluated in an international Phase I/II study in patients with relapsed or refractory AML. Its Luxeptinib is being evaluated in a Phase I a/b trial in patients with relapsed or refractory B cell malignancies, and in a separate Phase I a/b trial in patients with relapsed or refractory AML or high-risk MDS. Its APTO-253 is a small molecule MYC oncogene inhibitor at the Phase Ia/b clinical trial stage of development for the treatment of patients with relapsed or refractory (R/R) blood cancers, including AML and high-risk MDS. Its APL-581 is a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. |
| Financial Overview |
| For the fiscal year ended 31 December 2022, Aptose Biosciences Inc revenues was not reported. Net loss decreased 36% to $41.8M. Lower net loss reflects Program costs Luxeptinib decrease of 54% to $8.4M (expense), Stock-based compensation decrease of 67% to $3M (expense), Program costs APTO-253 decrease of 96% to $141K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.73 to -$0.45. |
| Employees: | 35 as of Dec 31, 2022 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $15.94M as of Dec 31, 2022 |
| Annual revenue (TTM): | $0.00M as of Dec 31, 2022 |
| EBITDA (TTM): | -$58.39M as of Dec 31, 2022 |
| Net annual income (TTM): | -$57.48M as of Dec 31, 2022 |
| Free cash flow (TTM): | -$44.46M as of Dec 31, 2022 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 92,368,000 as of Dec 31, 2022 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
US Quotes Data provided by IEX. Additional price data powered by Twelve Data. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
Interactive technical study charts by TradingView. Copyright © 2023 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.